Antithrombin Market Size
| Study Period | 2019 - 2029 |
| Base Year For Estimation | 2023 |
| Forecast Data Period | 2024 - 2029 |
| CAGR | 4.30 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Antithrombin Market Analysis
The antithrombin market is expected to register a CAGR of 4.3% over the forecast period.
The impact of COVID-19 on the antithrombin market was substantial in the initial phase owing to factors such as the closure of manufacturing facilities and research and development activities. However, the increasing use of antithrombin in COVID-19 patients has accelerated the demand for these products within the market. For instance, as per the report published by Acta Haematologica in December 2022, in severe COVID-19 patients, low antithrombin activity is linked to mortality as well as pro-inflammatory and prolonged hypercoagulable states. Antithrombin is a promising therapeutic target for future research in COVID-19 infection because of its anti-thromboinflammatory characteristics and is expected to attain growth in the market over the coming years.
The factors that drive the market include increasing coagulation diseases and open heart surgeries and increasing usage of diagnostic kits using antithrombin. Antithrombin is crucial since it stops excessive blood clotting. Due to the rise in chronic conditions like heart disease and kidney disease, the usage of antithrombin in surgical procedures has increased. Antithrombin is required during surgery to stop blood clots from forming. Hence, an increase in surgical procedures due to chronic diseases and a rise in antithrombin insufficiency have led to an increase in antithrombin demand, which will help the market grow.
For instance, according to the British Heart Foundation's 2022 report, in the United Kingdom, 7.6 million people suffer from heart and circulation conditions. Furthermore, these figures may continue to climb as a result of underlying conditions that affect the heart and circulatory system, an aging and growing population, as well as other factors. Hence, the high burden of heart and circulatory diseases raises the demand for surgical procedures, thereby increasing the usage of antithrombin and is expected to drive the market over the study period.
Furthermore, in December 2022, Octapharma stated that the ATN-06 study is investigating the use of Atenativ, a Plasma-Derived Antithrombin Concentrate, in people with congenital antithrombin deficiency undergoing surgery or childbirth. Thus with new studies on antithrombin deficiency treatments, the demand for antithrombin drugs increases, which is expected to drive the market over the forecast period.
However, the alternative supplements and the high cost of antithrombin therapy are expected to hinder the growth of the market over the forecast period.
Antithrombin Market Trends
This section covers the major market trends shaping the Antithrombin Market according to our research experts:
Therapeutics Segment is Expected to Hold a Large Market Share Over the Forecast Period
Antithrombin can be used as a treatment option in conditions like cardiac surgeries and in genetic conditions like hereditary antithrombin deficiency. Hereditary antithrombin deficiency, also known as antithrombin III deficiency or AT III deficiency, is a disorder in which individuals are at increased risk for developing blood clots and causing various heart diseases. Approximately 50% of individuals with Hereditary antithrombin deficiency will develop one or more clots in their lifetime, usually after adolescence which need proper treatment with antithrombin. Hence, the segment is expected to drive the market over the study period.
Furthermore, new research studies on the treatment of various antithrombin deficiencies can expand the applications of various drugs and help the market to grow over the study period. For instance, the study report published by the journal Thrombosis Update in December 2021 recommended using low molecular weight heparin (LMWH) during pregnancy with regular anti-Xa monitoring to ensure that women receive adequate antithrombotic therapy. Due to the effectiveness of LMWH activating antithrombin, substantial doses of LMWH are typically needed in people with antithrombin deficiency. Hence, with new studies, the usage of antithrombin drugs increases, which is expected to drive the market over the study period.
Asia-Pacific is Expected to be the Fastest Growing Region Over the Forecast Period
The Asia-Pacific region is expected to show high growth due to developing nations such as India and China that are embracing new treatment procedures and techniques to combat various diseases. The increase in non-refundable incomes in developing countries and their increasing capability to invest more money in advanced healthcare creates more opportunities for the market in the Asia Pacific. Furthermore, the rising burden of old age, along with increasing thrombosis diseases and new studies for antithrombin deficiency in the region, is expected to drive the market over the forecast period.
The population of the elderly in India has been increasing, which is a major factor driving the market in the region. For instance, as per the study by NSO, in 2021, the proportion of the elderly population in India was projected to be 10.1% in 2021 and 13.1% in 2031. As the elderly population increases, the risk of thrombosis is high and is expected to have an increased demand for antithrombin treatment and drive the market.
Furthermore, the new studies on antithrombin deficiency in the region are expected to increase the products of antithrombin and drive the market. For instance, as per the Frontiers in Neurology in June 2022, antithrombin deficiency is caused by various reasons, one of which is by inherited variants in the SERPINC1 gene. Hence, the SERPINC1 gene test is useful in determining the cause of antithrombin deficiency-related arterial thrombosis, especially ischemic stroke. Thus, the new studies in antithrombin deficiency help to increase the usage of specific diagnostic products and drive the market over the forecast period.
Antithrombin Industry Overview
The antithrombin market is moderately competitive and consists of several major players. Some of the major market players are CSL Limited, Grifols SA, Takeda Pharmaceuticals, Octapharma AG, LFB USA, Axis-Shield Plc, Siemens AG, Thermo Fisher Scientific, and Lee Biosolutions Inc.
Antithrombin Market Leaders
-
Octapharma AG
-
LFB USA
-
Takeda Pharmaceutical Company Limited
-
Grifols, S.A
-
CSL
*Disclaimer: Major Players sorted in no particular order
Antithrombin Market News
- February 2022: Grifols entered a collaboration with Endpoint Health, Inc. to develop and commercialize an Antithrombin III (AT-III) therapy to treat Sepsis. As part of the agreement, Grifols will contribute its industry-leading expertise in plasma-protein therapies and be the exclusive supplier of AT-III, a plasma protein that treats patients with blood clotting issues.
- February 2022: Techdow USA Inc., a vertically integrated generic injectables company, launched its Heparin Sodium Injection, USP, in the United States market.
Antithrombin Market Report - Table of Contents
1. INTRODUCTION
- 1.1 Study Assumptions & Market Definition
- 1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
- 4.1 Market Overview
-
4.2 Market Drivers
- 4.2.1 Increasing Coagulation Diseases and Open Heart Surgeries
- 4.2.2 Increasing Usage of Diagnostic Kits Using Antithrombin
-
4.3 Market Restraints
- 4.3.1 Adoption of Alternative Supplements due to High Cost of Antithrombin Therapy
-
4.4 Porter Five Forces
- 4.4.1 Threat of New Entrants
- 4.4.2 Bargaining Power of Buyers/Consumers
- 4.4.3 Bargaining Power of Suppliers
- 4.4.4 Threat of Substitute Products
- 4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
-
5.1 By Usage
- 5.1.1 Therapeutics
- 5.1.2 Diagnostics
- 5.1.3 Research
- 5.1.4 Other
-
5.2 By Source
- 5.2.1 Human
- 5.2.2 Recombinant Goat Milk
- 5.2.3 Others
-
5.3 By Type
- 5.3.1 Anticoagulant
- 5.3.2 Antiplatelet
- 5.3.3 Thrombolytic Drugs
-
5.4 By Route of Administration
- 5.4.1 Oral
- 5.4.2 Parenteral
-
5.5 Geography
- 5.5.1 North America
- 5.5.1.1 United States
- 5.5.1.2 Canada
- 5.5.1.3 Mexico
- 5.5.2 Europe
- 5.5.2.1 Germany
- 5.5.2.2 United Kingdom
- 5.5.2.3 France
- 5.5.2.4 Italy
- 5.5.2.5 Spain
- 5.5.2.6 Rest of Europe
- 5.5.3 Asia-Pacific
- 5.5.3.1 China
- 5.5.3.2 Japan
- 5.5.3.3 India
- 5.5.3.4 Australia
- 5.5.3.5 South Korea
- 5.5.3.6 Rest of Asia-Pacific
- 5.5.4 Middle East and Africa
- 5.5.4.1 GCC
- 5.5.4.2 South Africa
- 5.5.4.3 Rest of Middle East and Africa
- 5.5.5 South America
- 5.5.5.1 Brazil
- 5.5.5.2 Argentina
- 5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
-
6.1 Company Profiles
- 6.1.1 CSL
- 6.1.2 Grifols, S.A
- 6.1.3 Takeda Pharmaceutical Company Limited
- 6.1.4 Octapharma AG
- 6.1.5 LFB USA
- 6.1.6 Endpoint Health, Inc.
- 6.1.7 Siemens Healthcare GmbH
- 6.1.8 Thermo Fisher Scientific
- 6.1.9 Medix Biochemica (Lee Biosolutions)
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
** Subject To AvailablityAntithrombin Industry Segmentation
As per the scope of the report, antithrombin is a substance in the blood that limits the blood's ability to clot (coagulation) and is the primary inhibitor of thrombin, which is required for the development of blood clots. The Antithrombin Market is segmented by Usage (Therapeutics, Diagnosis, Research, and Others), Source (Human, Recombinant Goat Milk, and Others), Type (Anticoagulant, Antiplatelet, and Thrombolytic Drugs), Route of Administration (Oral and Parenteral), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The report offers the value (in USD million) for the above segments.
| By Usage | Therapeutics | |
| Diagnostics | ||
| Research | ||
| Other | ||
| By Source | Human | |
| Recombinant Goat Milk | ||
| Others | ||
| By Type | Anticoagulant | |
| Antiplatelet | ||
| Thrombolytic Drugs | ||
| By Route of Administration | Oral | |
| Parenteral | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Geography | Europe | Germany |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Rest of Europe | ||
| Geography | Asia-Pacific | China |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| Rest of Asia-Pacific | ||
| Geography | Middle East and Africa | GCC |
| South Africa | ||
| Rest of Middle East and Africa | ||
| Geography | South America | Brazil |
| Argentina | ||
| Rest of South America |
Antithrombin Market Research FAQs
What is the current Antithrombin Market size?
The Antithrombin Market is projected to register a CAGR of 4.30% during the forecast period (2024-2029)
Who are the key players in Antithrombin Market?
Octapharma AG, LFB USA, Takeda Pharmaceutical Company Limited, Grifols, S.A and CSL are the major companies operating in the Antithrombin Market.
Which is the fastest growing region in Antithrombin Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Antithrombin Market?
In 2024, the North America accounts for the largest market share in Antithrombin Market.
What years does this Antithrombin Market cover?
The report covers the Antithrombin Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Antithrombin Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Antithrombin Industry Report
Statistics for the 2024 Antithrombin market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Antithrombin analysis includes a market forecast outlook to 2029 and historical overview. Get a sample of this industry analysis as a free report PDF download.
